154 related articles for article (PubMed ID: 37985276)
21. Dopamine agonist-induced impulse control disorders in a patient with prolactinoma.
Almanzar S; Zapata-Vega MI; Raya JA
Psychosomatics; 2013; 54(4):387-91. PubMed ID: 23261076
[No Abstract] [Full Text] [Related]
22. Treating prolactinomas with dopamine agonists: always worth the gamble?
Noronha S; Stokes V; Karavitaki N; Grossman A
Endocrine; 2016 Feb; 51(2):205-10. PubMed ID: 26336835
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal analysis of impulse control disorders in Parkinson disease.
Corvol JC; Artaud F; Cormier-Dequaire F; Rascol O; Durif F; Derkinderen P; Marques AR; Bourdain F; Brandel JP; Pico F; Lacomblez L; Bonnet C; Brefel-Courbon C; Ory-Magne F; Grabli D; Klebe S; Mangone G; You H; Mesnage V; Lee PC; Brice A; Vidailhet M; Elbaz A;
Neurology; 2018 Jul; 91(3):e189-e201. PubMed ID: 29925549
[TBL] [Abstract][Full Text] [Related]
24. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
Burlacu MC; Maiter D; Duprez T; Delgrange E
Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
[TBL] [Abstract][Full Text] [Related]
25. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
26. Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma.
Bulwer C; Conn R; Shankar A; Ferrau F; Kapur S; Ederies A; Korbonits M; Spoudeas HA
Clin Endocrinol (Oxf); 2017 Jun; 86(6):862-864. PubMed ID: 28346715
[No Abstract] [Full Text] [Related]
27. Screening for impulse control disorders in Parkinson's disease and dopamine agonist use: a study of pharmacokinetic and psychological risk factors.
Contin M; Lopane G; Marini L; Mohamed S; Sambati L; De Massis P; Guarino M; Sermi S; Persichella C; Cortelli P; Calandra-Buonaura G
Neurol Sci; 2023 Feb; 44(2):565-572. PubMed ID: 36350455
[TBL] [Abstract][Full Text] [Related]
28. A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists.
Rizos A; Sauerbier A; Antonini A; Weintraub D; Martinez-Martin P; Kessel B; Henriksen T; Falup-Pecurariu C; Silverdale M; Durner G; Røkenes Karlsen K; Grilo M; Odin P; Chaudhuri KR;
Eur J Neurol; 2016 Aug; 23(8):1255-61. PubMed ID: 27170229
[TBL] [Abstract][Full Text] [Related]
29. Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma.
Thondam SK; Alusi S; O'Driscoll K; Gilkes CE; Cuthbertson DJ; Daousi C
Clin Neuropharmacol; 2013; 36(5):170-2. PubMed ID: 24045609
[TBL] [Abstract][Full Text] [Related]
30. Impulse control disorders in Parkinson's disease.
Weintraub D; Potenza MN
Curr Neurol Neurosci Rep; 2006 Jul; 6(4):302-6. PubMed ID: 16822350
[TBL] [Abstract][Full Text] [Related]
31. Impulse Control and Related Disorders in Parkinson's Disease.
Weintraub D; Claassen DO
Int Rev Neurobiol; 2017; 133():679-717. PubMed ID: 28802938
[TBL] [Abstract][Full Text] [Related]
32. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
Yarman S; Kurtulmus N; Bilge A
Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
[TBL] [Abstract][Full Text] [Related]
33. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
Elenkova A; Shabani R; Kalinov K; Zacharieva S
Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808
[TBL] [Abstract][Full Text] [Related]
34. The Role of Dopamine Agonists in Pituitary Adenomas.
Giraldi EA; Ioachimescu AG
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):453-474. PubMed ID: 32741482
[TBL] [Abstract][Full Text] [Related]
35. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
De Sousa SM; Chapman IM; Falhammar H; Torpy DJ
Endocrine; 2017 Feb; 55(2):618-624. PubMed ID: 27601019
[TBL] [Abstract][Full Text] [Related]
36. Association of dopamine agonist use with impulse control disorders in Parkinson disease.
Weintraub D; Siderowf AD; Potenza MN; Goveas J; Morales KH; Duda JE; Moberg PJ; Stern MB
Arch Neurol; 2006 Jul; 63(7):969-73. PubMed ID: 16831966
[TBL] [Abstract][Full Text] [Related]
37. Impulse control disorders associated with dopaminergic drugs: A disproportionality analysis using vigibase.
De Wit LE; Wilting I; Souverein PC; van der Pol P; Egberts TCG
Eur Neuropsychopharmacol; 2022 May; 58():30-38. PubMed ID: 35189453
[TBL] [Abstract][Full Text] [Related]
38. The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: A cross-sectional multicenter study.
Vela L; Martínez Castrillo JC; García Ruiz P; Gasca-Salas C; Macías Macías Y; Pérez Fernández E; Ybot I; Lopez Valdés E; Kurtis MM; Posada Rodriguez IJ; Mata M; Ruiz Huete C; Eimil M; Borrue C; Del Val J; López-Manzanares L; Rojo Sebastian A; Marasescu R
J Neurol Sci; 2016 Sep; 368():150-4. PubMed ID: 27538621
[TBL] [Abstract][Full Text] [Related]
39. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
[TBL] [Abstract][Full Text] [Related]
40. Frequency of pituitary tumor apoplexy during treatment of prolactinomas with dopamine agonists: a systematic review.
Carija R; Vucina D
CNS Neurol Disord Drug Targets; 2012 Dec; 11(8):1012-4. PubMed ID: 23244423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]